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Carcinoid heartAbstract Objectives: This study aims at reporting 2 cases of primary ovarian carcinoid tumor,
and providing an adequate registry of such cases and how they were managed.
Methods: 2 female patients with primary ovarian carcinoid were diagnosed and treated in our cen-
ter. Discussion of their presentation, pathology and treatment is entitled. Also a thorough search of
all published registries and case reports of ovarian carcinoid was done with analysis of reported
data.
Results: 164 cases of primary ovarian carcinoid tumor were detected since 2005 with the predom-
inance of the insular variant. Carcinoid syndrome occurs in nearly 14% of these cases. Most of the
cases were treated with hysterectomy. Unfortunately, the prognosis was not documented in most
series.
Conclusion: Primary ovarian carcinoid is a relatively rare disease with an indolent course and excel-
lent outcome. Carcinoid syndrome, especially carcinoid heart disease may worsen the prognosis.
Total abdominal hysterectomy with bilateral salpingo-oophorectomy has been commonly used as
the treatment of choice of primary ovarian carcinoid tumors.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
Ovarian carcinoid tumors may be primary or metastatic
(mostly from GIT origin). Differentiation is usually difficult,but bilaterality, peritoneal deposits, absence of teratomatous
element, and lymphovascular invasion are signs of metastatic
carcinoid [1]; more recent studies suggested that immunohisto-
chemistry with CDX2 may be of value in differentiating carci-
noids of GIT origin [2]. Primary carcinoid tumor of the ovary
represents less than 1% of all carcinoid tumors and less than
0.1% of all ovarian neoplasms. Two thirds of these tumors
manifest as a localized lesion, while about one third presents
with distant spread [3]. Most tumors are seen in peri-
menopausal women, commonly presenting with ovarian
heterogeneous mass, or as an incidental finding in abdominal
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WHO, there are four major variants of primary ovarian carci-
noid: insular, trabecular, strumal, mucinous and mixed (insu-
lar and trabecular) [4]. 30% of patients with carcinoids have
symptoms of the carcinoid syndrome, mainly affecting patients
with insular type, while it rarely occurs with trabecular type.
Extremely rare cases presented with an intractable constipa-
tion mainly due to peptide YY which inhibits intestinal motil-
ity [5,6]. Primary ovarian carcinoid may occur on top of
teratoma or in an otherwise normal ovary. Surgery remains
the cornerstone for treatment of localized cases with excellent
prognosis.Methods
This study reports 2 different cases of primary ovarian carci-
noid who attended the Oncology Center Mansoura University
(OCMU) in 2014, and aims to review and register all published
cases since 2005 till March 2016.Case report one
Malignant ovarian carcinoid on top of teratoma.
Female patient 59 years old, postmenopausal with 5 off-
spring, hypertensive and hepatic (HCV + ve) with no surgical
history, presented with abdominal pain, enlargement and
bloating to her gynecologist, who recommended computerized
tomography. CT revealed right ovarian mass 9  11  7.3 cm
mostly cystic with irregular outline with omental metastasis
and moderate ascites.
The patient was referred to our center (OCMU) where revi-
sion of CT suggested ovarian cancer, and after multidisci-
plinary panel discussion the decision was exploration.
Exploration was done on March 2014 under general anes-
thesia with a midline incision where about one liter of ascites
was aspirated and sent for cytology, followed by right
salpingo-oophrectomy and frozen section. The frozen pathol-
ogy revealed malignant ovarian neoplasm, so complete staging
laparotomy in the form of total abdominal hysterectomy, con-
tralateral salpingo-oophrectomy, omentectomy, bilateral iliac
lymphadenectomy and random peritoneal biopsies was done.
Postoperative pathology showed a malignant carcinoid
tumor of the right ovary mostly on top of teratoma (insular
variant) with no lymphovascular emboli with Ki67 <2%
(Fig. 1). Left ovary, omentum and peritoneal biopsies were
free with reactive hyperplasia of 14 dissected lymph nodes.
Patient was sent home at 4th day postoperative with drain
output of 300c.c serous discharge.
The patient was readmitted one week later to the ICU with
wound infection, low grade fever and disturbed conscious
level. Investigations showed mildly elevated liver enzymes
(SGOT= 65), mild deterioration of renal function
(Cr = 2.3), leucocytosis (20,000) mainly neutrophilia, throm-
bocytosis (620), hyperbilirubinemia (1.5), respiratory alkalosis
(PH = 7.42, CO2 = 35 and HCO3 = 21), hypernatremia
(160), hypocalcemia (Ca = 6.5) and normal potassium
(K = 5). The condition was recognized as severe sepsis leading
to hepatic pre-coma and unusual electrolyte disturbances. The
patient was managed by wound drainage, liver supports, IV
fluids and electrolyte replacement.The patient was re-discharged 5 days latter with good gen-
eral status.
No chemotherapy was given and patient was scheduled for
follow up every 6 months in 1st two years. No evidence of
recurrence was detected in radiology after two years of follow
up.
Case report two
Pure ovarian carcinoid tumor.
Female patient was aged 48 years with liver cirrhosis and
surgical history of splenectomy followed by hernioplasty for
incisional hernia one year later. CT (pre-excision) was done
revealing large, well defined, bilobed solid and cystic mass in
the right adenexal region with multiple areas of calcifications
contacting and compressing right psoas muscle 6  11 cm sug-
gestive of dermoid cyst. Left simple ovarian cyst 3 cm was also
detected.
Unilateral right salpingo-oophrectomy was done outside
our center. Postoperative pathology revealed a carcinoid
tumor (trabecular variant) with positive chromogranin and
synaptophysin, and Ki67 <2% (Fig. 2). CT after the opera-
tion was free. Serum 5-HIAA= 8.9.
Multidisciplinary panel at OCMU decision was completion
hysterectomy, omentectomy and appendectomy which was
done at November 2014 with postoperative pathology free of
tumor tissue. Patient remains disease free after one and half
year of follow up.
Registry
Although population based registries of primary ovarian carci-
noid tumors are deficient, multiple researchers had made
efforts on registering and analyzing reported cases of these
tumors. The last of this published registry up to our knowledge
was Modlin et al. [3] at 2003. A thorough search on pubmed,
medline and google was done with headings (primary ovarian
carcinoid, carcinoid on top of teratoma and malignant trans-
formation of teratoma) and all reported cases since 2005 till
March 2016 were registered (Table 1).
From the collected data we recognized 52 cases with insular
variant (commonest pathology), 21 cases with trabecular vari-
ant, 20 cases with strumal variant, mixed variant in 4 cases and
mucinous in 1 case with the remaining 66 case non-specified
(Fig. 3). The mean age was 50 years. The average tumor size
was about 11 cm. Most of the cases were pure carcinoid (68
cases) while carcinoid transformation of a benign teratoma
occurs in 45 cases (51 cases were unreported) (Fig. 4).
Functioning ovarian carcinoid causing endocrine symp-
toms occurs rarely (only 25 cases). 14 cases manifested with
carcinoid heart disease (2 of which were diagnosed in post-
mortem pathology). Another 9 cases manifested with constipa-
tion, which was related to polypeptide secretion. Only one case
presented with Cushing syndrome and one with hyperinsuline-
mia (Fig. 5). More interestingly all cases documented with con-
stipation were strumal variant and none of the cases with
trabecular variant were functioning.
Associated tumors occur in only 16 cases (mucinous cys-
tadenoma = 5, contra-lateral ovarian epithelial cancer = 1,
liver metastasis = 2, strumal thyroid cancer + breast
cancer = 1, endometrial cancer + gliomatosis peritonii = 1,
Figure 1 Case one insular carcinoid on top of teratoma. (A) monotonous cells with granular salt and pepper chromatin (H&E.400).
(B) Positive cytoplasmic reaction for chromogranin (200). (C) Positive cytoplasmic reaction for CK (200). (D) Strong reaction for
synaptophysin (200). (E) Cytoplasmic reaction for NSE (400). (F) The only field showing scattered positive nuclei for Ki67, less than
2% of the tumor (200).
Figure 2 Case two pure ovarian carcinoid (trabecular variant). (A) Cords of monotonous cells separated by fibrovascular stroma (H.
&E.200). (B) Higher magnification showing moderate amount of eosinophilic cytoplasm hyperchromatic nuclei and inconspicuous
nucleoli (H.&E.400). (C) Positive IHC reaction for chromogranin in tumor cells (400).
Primary ovarian carcinoid 269teratoma of contra-lateral ovary = 1, nodal recurrence = 1,
gall bladder carcinoid = 1, ovarian ependymoma+MEN1 = 1, pseudomyxoma peritonii = 1, colonic
lymphangiocele = 1).
Table 1 Show reported cases of ovarian carcinoid since 2005 with their full data.
No. Variant Age Size Overlying
teratoma
Functional
presentation
Associated tumor Treatment
Kopf et al. [7] 1 case Insular 79 18 cm No No No BSO
DiazMontes et al.
[8]
1 case Insular 80 6 cm Yes Yes No TAHBSO+ staging
Chatzipantelis et al.
[9]
1 case Insular 57 // Yes (bilateral) No Mucinous cystadenoma //
Zhao et al.* [10] 42
cases
// // // // // // //
Morken et al. [11] 1 case // // // No Insulin secreting No //
Kawano et al. [12] 1 case Strumal // // No Constipation Contralateral ovarian epithelial
cancer
Oophorectomy
Nyktari et al. [13] 1 case // 66 // Yes Yes (CHD) No TAHBSO
Bonaros et al. [14] 1 case // // // // Yes (CHD) // //
Djordjevic et al.
[15]
1 case Trabecular // // Yes
(recurrent)
No Liver mets Excision
Chargui et al. [16] 3
cases
// 50 // No No No SO followed by TAH
23
28
Somak et al. [17] 1 case Mixed 55 11 cm No No No TAHBSO
Dotto et al. [1] 1 case Insular 50 21.5 cm No No No //
Pelosi et al. [18] 1 case Strumal 69 21 cm Yes No Strumal thyroid cancer
+ breast cancer
CBS + Oophrectomy
Lagoudianakis
et al. [19]
1 case Insular 44 // Yes No No SO
Engohan-Aloghe
et al. [20]
1 case Insular 75 9 cm No No No TAHBSO+ staging
Rabban et al. [21] 16
case
6insular + 6strumal + 3trabecular
+ 1mucinous
average
52
About
3.4 cm
Yes (10/16) // No //
Takahashi et al.
[22]
1 case // 52 10 cm No Yes (CHD) No TAHBSO
Cheng et al. [23] 1 case // // // // // // //
Guney et al. [24] 1 case // 54 9 cm Yes No No TAHBSO
Gungor et al. [25] 1 case // 47 4 cm Yes No No TAHBSO+ staging
+ appendectomy
Tangour et al. [26] 1 case // // // // // // //
Chen et al. [27] 1 case Strumal // // No Constipation No Lap. oophrectomy
Kurabayashi et al.
[28]
1 case Strumal 34 // No No No //
Bai et al. [29] 1 case Trabecular 55 6.2 cm No No No TAHBSO
Aggeli et al. [30] 1 case // 60 // No Yes (CHD) No //
Alexander et al. [31] 1 case // // // Yes
(recurrent)
No Endometrial cancer
+ gliomatosis peritonii
TAHBSO
Roberts et al. [32] 1 case // 53 // No Yes (CHD) liver mets //
Levin et al. [33] 1 case // // // // // // //
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Shin et al. [34] 1 case // 60 12 cm No Yes (CHD) // Oophrectomy + chemotherapy
Djurovic et al. [35] 1 case // 49 // No Yes No TAHBSO
Matsunami et al.
[36]
1 case Strumal 45 // No Constipation Teratoma of contralateral
ovary
BSO
Takeuchi et al. [37] 2
cases
Strumal 72 // No No Mucinous cystadenoma //
Insular 77 10 cm
Hinshaw et al. [38] 1 case Strumal 74 8.5 cm Yes No Adenocarcinoma + strumal
thyroid cancer
Robotic assisted Lap. TAHBSO
+ staging
Buda et al. [39] 1 case Insular 78 13 cm Yes Yes (CHD) // TAHBSO+ staging
Takatori et al. [40] 1 case Strumal 48 6 cm No Constipation No Adenexectomy
Lenicek et al. [4] 2
cases
Strumal // // // // // //
Ulker et al. [41] 2
cases
Insular 55 12 No No No TAHBSO+ staging
Trabecular 39 11 SO
Yamaguchi et al.
[42]
1 case Strumal 24 12 cm No Constipation Mucinous cystadenoma Oophrectomy
Hayashi et al. [43] 1 case Strumal 45 // // // // //
Ouyang et al. [44] 1 case // // // // Constipation // //
Amano et al. [45] 1 case // 67 7 cm No Yes (CHD) Nodal recurrence Excision
Bassi et al. [46] 1 case // 45 20rt
+ 15lt
No No Gall bladder carcinoid TAHBSO+ staging + Radical
cholecystectomy
Petousis et al. [47] 1 case Trabecular 28 10.5 cm Yes N0 No Lap. Excision
Desouki et al. [2] 46
case
35insular + 11trabecular // // 30 No // // //
16 Yes
Ting et al. [48] 1 case Insular // // Yes No No BSO
Horikawa et al. [49] 1 case Trabecular 57 // Yes // // //
Huang et al. [50] 1 case // 46 // Yes (bilateral) Cushing No BSO
Spaulding et al. [51] 1 case Trabecular 51 5.5 cm Yes No Ovarian ependymoma
+MEN1
Robotic TAHBSO
Tome et al. [52] 1 case // // // // // // //
Sharma et al. [53] 1 case Trabecular 50 8 cm Yes No No TAHBSO
Muller et al. [54] 1 case strumal 34 // No Constipation No //
Dessauvagie et al.
[55]
1 case // 69 // No Yes (CHD) No //
Quin˜onez et al. [56] 1 case Mixed // Yes No Pseudomyxoma peritonii //
Agarwal et al. [57] 1 case // 75 // No Yes (CHD) No SO
Erdinbatar et al.
[58]
1 case Mixed 70 6 cm No Constipation No TAHBSO+ staging
Tarcoveanu et al.
[59]
1 case Strumal 55 7 cm No No Colonic lymphangioma Laparoscopic SO
Kolouch et al. [60] 1 case Insular 77 // No Yes (CHD) No TAHBSO
Kim et al. [61] 1 case Mixed 39 9 cm Yes NO No SO
CHD= carcinoid heart disease, TAHBSO= total abdominal hysterectomy and bilateral salpingo-oophrectomy, Lap. = laparoscopic, // = unmentioned.
* Zhao et al. 40 cases were registered by armed forces institute of pathology before 2005 but were not published till 2007 and were included in previous registry so included.
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Figure 3 Incidence of different pathological variants of ovarian
carcinoid.
27% 
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32% 
on top of teratoma pure unspeciﬁed
Figure 4 Relation of ovarian carcinoid to Teratoma.
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4% 4% 
(only 25 case =15%)
Heart disease Conspaon Cushing Hyperinsulinemia
Figure 5 Hormonal presentation of ovarian carcinoid tumors.
272 I.H. Metwally et al.Treatment was extremely variable, most cases underwent
total abdominal hysterectomy and bilateral salpingo-
oophrectomy (13 cases); three of them completed surgery after
initial oophrectomy and paraffin section. Other surgeons pre-
ferred complete staging laparotomy with lymphadenectomy
as for epithelial ovarian cancer (8 cases). Bilateral salpingo-
oophrectomy was done in 6 cases; while fertility sparing sur-
gery (unilateral salpingo-oophrectomy) was done in 10 cases
with no documentation of long term follow up except one case
with 2 year disease free survival. In the remaining 127 cases
treatment was not reported.From the collected data there were 164 cases of primary
ovarian carcinoid reported since the beginning of 2005 till
March 2016 adding to this our 2 case reports, making a total
of 658 cases of primary ovarian carcinoid reported since first
diagnosed at 1939 till now.
Is there a rule for appendectomy in treatment of primary ovarian
carcinoid
Although it is a commonly performed practice aiming to
exclude appendiceal origin, there is no consensus on it and
all cases were negative in our review and in our case report.
In spite of this some experts prefer doing appendectomy in
the mucinous variant of carcinoid.
Discussion
Neuroendocrine tumors are relatively rare tumors arising from
APUD cells of neuroectodermal origin (previously called
APUDomas); they include Medullary thyroid cancer, Merkel
cell carcinoma, pheochromocytoma, pancreatic islet cell
tumors, carcinoid tumors (bronchopulmonary, GIT and thy-
mus) and neuroendocrine tumors of the gynecological tract.
Neuroendocrine tumors are usually sporadic, but may arise
in the context of syndromes as MEN, Von Hippel Lindau
and neurofibromatosis [62]. Neuroendocrine tumors of the
ovary include: poorly differentiated high grade variants (small
cell & large cell NETs) and well differentiated indolent variants
known as carcinoids [63].
Ovarian carcinoid tumors were first described in 1939 by
Stewart et al. [64]. Since then, multiple case reports were pub-
lished. At 2000 Soja et al. published an important analysis of
ovarian carcinoid tumors registered worldwide [65]. In his
paper 329 cases of primary ovarian carcinoid were analyzed
with 57% occurring on top of teratoma and 47% occurring
as pure form. He concluded that pure forms were larger in size
(average 8.9 cm), had higher rates of metastases (22%) and a
higher incidence of carcinoid syndrome (22.9%) [57]. The sec-
ond large registry of primary ovarian carcinoid was Modlin
et al. [3] at 2003 in which 492 cases were described. Approxi-
mately 66% of them were localized lesions, while about 31%
present with distant spread. Unfortunately, in his paper Mod-
lin did not differentiate cases occurring as pure form from
those occurring on top of teratoma.
Mature teratoma of the ovary is known to be the most com-
mon ovarian tumor, representing 20% of all ovarian neo-
plasms. Malignant transformation of teratoma was
described, although rare. The commonest overlying malig-
nancy was squamous cell carcinoma [66], followed by adeno-
carcinoma then carcinoid tumor.
Carcinoid tumors secrete a great variety of neurohumoral
substances including; serotonin, histamine, tachykinin, brady-
kinin, kallikrein, corticotrophin, substance P, motilin, and
prostaglandins [67]. Persistent body exposure to large quanti-
ties of these hormones and amines result in carcinoid syn-
drome with the classic triad of; flushing of arms and face,
wheezes, and diarrhea. Normally, carcinoid syndrome does
not occur with an intestinal carcinoid until it has metastasized
or in the presence of hepatic dysfunction or hepatic shunts (as
TIPS), because of the efficient hepatic detoxification of
secreted substances. However, functioning primary ovarian
Primary ovarian carcinoid 273carcinoid tumors can cause these symptoms directly, because
their venous drainage bypasses the portal venous system [68].
Trabecular carcinoid variant was never associated with carci-
noid syndrome. Carcinoid syndrome was absent in both cases
in our report.
The insular type is the commonest variant of primary ovar-
ian carcinoid, followed by the strumal and trabecular types;
while mucinous carcinoids are the least common. Bearing in
mind that metastatic carcinoids in the ovary are mostly of
insular type, the diagnostic problem is in these cases, and are
only occasionally with trabecular or mucinous types [21].
Immunohistochemistry is crucial in the diagnosis of pri-
mary carcinoid tumors of the ovary. Synaptophysin and chro-
mogranin are the classic markers. CD56 may be used, but is
nonspecific. Estrogen and progesterone receptors are always
negative, in contrast to adenocarcinoma. TTF1 and CDX2
may be used to differentiate primary from secondary carcinoid
tumors [10]. Most primary ovarian carcinoids are stage I on
FIGO system with tumor confined to one ovary, while few
cases with advanced disease were reported [7].
Clinical and pathological prognostic factors of the neo-
plasm are the basic determinants of the therapeutic strategy
in these rare cases, because of the absence of evidence-based
guidelines. Cyst wall invasion, intra-operative rupture of the
ovarian tumor and disseminated tumor are considered unfa-
vorable prognostic factors [69].
Premenopausal women with tumors confined to the ovary
may be treated with fertility-sparing surgery, as tumors are
usually unilateral and carry a good prognosis, but careful
staging to exclude occult metastases is important. However,
in the absence of controlled trials to validate this approach,
hysterectomy with bilateral salpingo-oophrectomy and surgi-
cal debulking of extra-ovarian spread and/or metastases is
the treatment of choice [47], using the commonly taught dic-
tum ‘‘diagnose as rare and treat as common”. In rare
patients with mucinous variant of ovarian carcinoid, omen-
tectomy and para-aortic lymph node dissection may also
be needed because these tumors spread mainly through lym-
phatics [63].
Anesthesia of those patients with carcinoid syndrome can
be challenging due to extreme hemodynamic lability and exag-
gerated physiologic responses to trivial stimuli. Recommenda-
tions include: titrated induction of anesthesia and avoidance of
catecholamines and sympathomimetic drugs because these
drugs may trigger a carcinoid crisis. In addition peri-
operative cover with an Octreotide infusion reduces the risks
[70–74].
Conclusion
Primary ovarian carcinoid is a rare tumor with only 658 cases
reported worldwide up-to-date. Diagnosis should be confirmed
by immunohistochemistry, and secondary carcinoid should be
excluded. Extensive sampling of any solid part within a mature
teratoma is emphasized not to miss a focus of carcinoid. Ade-
quate treatment is not well defined, but surgery still the main
line with chemotherapy reserved for those with high prolifera-
tive index as measured by Ki67. Somatostatin analog is only
used for those with functioning tumors as confirmed by urine
5-HIAA and/or serum chromogranin.Conflict of interest
We have no conflict of interest to declare.
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